Kabra Drugs

{
  "main_header": {
    "sid": 271637,
    "name": "Kabra Drugs",
    "stock_name": "Kabra Drugs",
    "full_name": "Kabra Drugs Ltd",
    "name_url": "stocks-analysis/kabra-drugs",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "28.97",
    "chg": 1.19,
    "chgp": "4.28%",
    "dir": 1,
    "prev_price": "27.78",
    "mcapval": "64.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524322,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE323K01017",
    "curr_date": "Jan 19",
    "curr_time": "",
    "bse_nse_vol": "59.68 k",
    "exc_status": "Active",
    "traded_date": "Jan 19, 2026",
    "traded_date_str": "2026 01 19",
    "score": "",
    "scoreText": "",
    "Live": 1,
    "market_time": 1,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/kabra-drugs-271637-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3703266",
        "imagepath": "",
        "date": "2025-11-14 23:52:54",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total ..."
      },
      {
        "title": "How has been the historical performance of Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-kabra-drugs-3699169",
        "imagepath": "",
        "date": "2025-11-13 23:25:50",
        "description": "Answer:\nThe historical performance of Kabra Drugs shows a consistent lack of revenue generation over the years, with net sales remaining at zero from March 2021 to March 2025, except for a nominal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, with only minor fluctuations in other operating income. The company's expenditures have increased significantly, particularly in employee costs, which rose from 0.03 Cr in March 2019 to 0.69 Cr in March 2025. This has led to a growing operating loss, with the operating profit (PBDIT) declining from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures follow a similar pattern, indicating increasing losses over the years. The company's equity capital increased sharply to 23.71 Cr in March 2025 from 4.39 Cr in the previous years, and reserves improved to 0.95 Cr from negative values, s..."
      },
      {
        "title": "When is the next results date for Kabra Drugs?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-kabra-drugs-3681427",
        "imagepath": "",
        "date": "2025-11-07 23:22:02",
        "description": "The next results date for Kabra Drugs is scheduled for 13 November 2025...."
      }
    ],
    "total": 52,
    "sid": "271637",
    "stock_news_url": "https://www.marketsmojo.com/news/kabra-drugs-271637"
  },
  "announcements": [
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "06-Jan-2026",
      "details": "Certificate pursuant to Regulations 74 (5)",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Outcome for Board Meeting Outcome For Outcome Of Board Meeting Held On 01St January 2026 As Per Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015.",
      "datetime": "01-Jan-2026",
      "details": "Outcome of Board meeting held on 01st January 2026.",
      "source": "BSE"
    },
    {
      "caption": "Closure of Trading Window",
      "datetime": "30-Dec-2025",
      "details": "Intimation of Closure of Trading Window",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

How has been the historical performance of Kabra Drugs?

2025-11-14 23:52:54

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation, with net sales remaining at zero from March 2021 to March 2025, except for a nominal figure of 0.01 Cr in March 2019. The total operating income also reflects this trend, with minimal other operating income recorded in previous years. The company has incurred increasing total expenditures, rising from 0.05 Cr in March 2020 to 1.72 Cr in March 2025, primarily driven by employee costs and other expenses. Operating profit has been negative throughout this period, with losses deepening from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures mirror this decline, showing losses that have increased over the years. On the balance sheet, shareholder's funds improved from -0.73 Cr in March 2023 to 24.65 Cr in March 2025, largely due to an increase in equity capital. Total ...

Read full news article

How has been the historical performance of Kabra Drugs?

2025-11-13 23:25:50

Answer: The historical performance of Kabra Drugs shows a consistent lack of revenue generation over the years, with net sales remaining at zero from March 2021 to March 2025, except for a nominal amount of 0.01 Cr in March 2019. The total operating income also reflects this trend, with only minor fluctuations in other operating income. The company's expenditures have increased significantly, particularly in employee costs, which rose from 0.03 Cr in March 2019 to 0.69 Cr in March 2025. This has led to a growing operating loss, with the operating profit (PBDIT) declining from -0.13 Cr in March 2019 to -1.08 Cr in March 2025. The profit before tax and profit after tax figures follow a similar pattern, indicating increasing losses over the years. The company's equity capital increased sharply to 23.71 Cr in March 2025 from 4.39 Cr in the previous years, and reserves improved to 0.95 Cr from negative values, s...

Read full news article

When is the next results date for Kabra Drugs?

2025-11-07 23:22:02

The next results date for Kabra Drugs is scheduled for 13 November 2025....

Read full news article

View All News